πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

7,888 results for β€œ1” Clear

  1. VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial
  2. VRDN-001 10 mg/kg

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial
  3. VRDN-001 Phase 3 Cohort (THRIVE)

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial
  4. VX-121/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    6 trials
  5. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 3 small molecule active

    1 trial
  6. VX-147 film-coated tablet, VX-147, Coated Placebo Tablet

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Proteinuric Kidney Disease (AMKD)

    phase 3 small molecule active

    1 trial
  7. VX-210

    Vertex Pharmaceuticals (Australia) Pty.

    Cervical Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial
  8. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Kalydeco 75 mg granules in sachet, Kalydeco 75 mg film-coated tablets, VX-770 75mg, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 150 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial
  9. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 75mg, VX-770 granules, Kaftrio 75 mg/50 mg/100 mg granules in sachet, Kalydeco 50 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 60 mg/40 mg/80 mg granules in sachet, VX-770 50mg, Kalydeco 59.5 mg granules in sachet, Kalydeco 25 mg granules in sachet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 granules, Ivacaftor 25 mg granules

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial
  10. VX-661 Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials
  11. VX-661/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial
  12. VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 50 mg granules in sachet

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial
  13. VX-880

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetes Mellitus, Type 1

    phase 3 mab active

    1 trial
  14. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial
  15. VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, Placebo for 75 mg Rimegepant, Placebo for 50 mg rimegepant, 50 mg oral lyophilisate, Placebo for 35 mg rimegepant, Placebo for 25 mg Rimegepant, 25 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial
  16. VYDURA 75 mg oral lyophilisate, matching placebo for 75 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Menstrual Migraine

    phase 3 small molecule active

    1 trial
  17. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial
  18. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic migraine

    phase 3 small molecule active

    1 trial
  19. VYEPTI 100 mg concentrate for solution for infusion, Nacl 0.9%

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial
  20. Valbenazine, Valbenazine, Placebo for valbenazine capsules

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial
  21. Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

    Sanofi-aventis Healthcare Pty Ltd

    Pneumococcal Immunization

    phase 3 small molecule active

    1 trial
  22. Vectibix 20 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer

    phase 3 small molecule active

    1 trial
  23. Vedolizumab SC 108 mg

    Takeda

    Crohn's Disease

    phase 3 small molecule completed

    1 trial
  24. Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid), Ruxolitinib (INCB018424) cream

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources